(Date:5/16/2008)...most from chemo after surgery, study says , ...f 15 genes may help determine which patients with ...ence a recurrence and, therefore, benefit the most...tension, the same genetic signature may also ident...cer who would be able to forego chemotherapy. ,...
(Date:5/16/2008)...e/ -- As tropical storms,continue to batter the af...yclone Nargis are vulnerable to diseases and other...ance, as exposure to the foul weather and,malnutri... "The people living in these conditions urgently ...et back on their feet," said David Meltzer,senior...
(Date:5/16/2008)... 2007, WASHINGTON, May 16 /PRNewswire-USNewswire/...eaths, the National Cancer Institute (NCI) investe...cancer research in 2007,according to updated stat..., The two other federal agencies with significant...ontrol and Prevention (CDC) and the,Department of ...
(Date:5/16/2008)... -- CryoCor, Inc. (Nasdaq:,CRYO), a medical device...thmias, announced today that on May 8, 2008, two a...plaint in the Superior Court of the State,of Calif...ach member of the,Board of Directors of CryoCor, C...laint is styled Secondido, et al. v. CryoCor, Inc....
Breaking Medicine News(10 mins):Health News:Gene Signature May Predict Recurrence of Lung Cancer 2Health News:Gene Signature May Predict Recurrence of Lung Cancer 3Health News:Myanmar Cyclone Survivors Face New Challenges 2Health News:Lung Cancer Still Lowest in Federal Funding 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 2Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 3Health News:CryoCor, Inc. Subject of Lawsuit Relating to Tender Offer and Merger 4(Date:5/15/2008)...mount of research reflects depth and breadth of, ...lop new treatments for dive...ht impact of Zometa(R), the leading IV, bisphospho... breast cancer, - Four oral sessions to feature R... of mTOR, including first results of RECORD-1 stud...
(Date:5/15/2008)...d TOULOUSE, France, May 15 /- Cerenis...aceutical company,developing HDL-related compounds... diseases, today announced that it has completed a...mpany,s lead product candidates.,CER-002 is a pero...a-specific agonist in development for the treatmen...
(Date:5/15/2008)...y Remains for an Antiplatelet Therapy that, Combin...mbination of Plavix/Iscover and Aspirin, Accor...THAM, Mass., May 15 /- Decision Resou...sory firms for pharmaceutical and,healthcare issue...ffers,improvement in patient compared to Sanofi-Av...
(Date:5/15/2008)...y 15 /- Omega 3 fatty acids bound to,... a credible natural,alternative and may have benef...nt in vivo French study reveals. While several stu...n hyperactivity, French researchers have,hypothesi... effects on,impulse control., These research find...
Breaking Medicine Technology:Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 2Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 3Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 4Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 5Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 6Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 7Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 8Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 9Strength and Innovation of Novartis Oncology Products and Pipeline With Potential to Improve Patient Treatment Demonstrated by More Than 170 Abstracts at ASCO Annual Meeting 10Cerenis Therapeutics Completes Phase I Clinical Trial of CER-002 for Treatment of Cardiovascular Disease 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 2Daiichi Sankyo/Eli Lilly's Effient and Astrazeneca's Ticagrelor May Offer Advantages in the Treatment of Post-Myocardial Infarction 3Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 2Omega 3 Fatty Acids Bound to Phospholipids has Potential Benefit for Attention-Deficit Hyperactivity Disorder (ADHD) 3Ceremeds OSTENE 28R 29 Improves Bone Fusion and Healing After Surgery New Study Shows 2045 1Ceremeds OSTENE 28R 29 Improves Bone Fusion and Healing After Surgery New Study Shows 2045 2Ceremeds OSTENE 28R 29 Improves Bone Fusion and Healing After Surgery New Study Shows 2045 3ADVENTRX Pharmaceuticals to Present at the Rodman 26 Renshaw 5th Annual Global Healthcare Conference 5333 1Chiltern Announces New Expansion in Portugal 19137 1Chiltern Announces New Expansion in Portugal 19137 2Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 1Providence Holy Cross Medical Center Ignores Community Environmental Concerns With Planned Expansion of Mission Hills Facility 19133 2...a from XL880, Phase II data from XL999 studies,sch...ns -, SOUTH SAN FRANCISCO, May 30, 2007 /PRNewswir...t data from clinical trials of,the company,s inves...nted at the 2007 American Society of Clinical Onco...ne 1 to 5 in Chicago,Illinois. , , -- Data fro...
...y 31, 2007 /PRNewswire-FirstCall/ -- Lev,Pharmaceu...day that,it has completed patient treatment in the...ial of C1-esterase inhibitor (C1-INH) for,heredita...d CHANGE,examined and evaluated the efficacy and ...cute HAE attacks and as,prophylactic treatment to ...
Other Medicine Technology:Six Abstracts Featuring Exelixis Compounds Accepted At ASCO,Conference 2Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema 2Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema 3Lev Pharmaceuticals Completes Phase III Prophylaxis Trial of,C1-Esterase Inhibitor for Hereditary Angioedema 4...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
...aboratories is a national reference laboratory and...rch and development. ARUP offers an extensive test...n clinical and anatomic pathology. Owned by the Un...de more than half of the nation's university teach...
Medicine Products: